Comparison · NCT03189719-1bf13b30
Pembrolizumab + SOC vs Placebo + SOC: Number of Participants Discontinuing Study Treatment Due to an AE
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pembrolizumab + SOC vs Placebo + SOC: Number of Participants Discontinuing Study Treatment Due to an AE. Trial comparisons, record NCT03189719-1bf13b30. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03189719-1bf13b30
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.243 | 0.202 | 0.289 | wilson | |
| Risk in group 2 | 0.2 | 0.162 | 0.244 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0432 | -0.0167 | 0.103 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.22 | 0.927 | 1.6 | log | |
| Odds ratio, group 1 over group 2 | 1.29 | 0.908 | 1.82 | log | |
| Number needed to treat, for one more participant with the outcome on Pembrolizumab + SOC than on Placebo + SOC | 23.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pembrolizumab + SOC | Participants received pembrolizumab 200 mg IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle. | 90 | 370 | OG000 |
| Group 2 | Placebo + SOC | Participants received placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle. | 74 | 370 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Discontinuing Study Treatment Due to an AE
- Description
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.
- Time frame
- Up to approximately 27 months
- Population
- All randomized participants who received at least one dose of study treatment were analyzed.
Source ClinicalTrials.gov
Trial
- Title
- First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
- NCT number
- NCT03189719
- Phases
- PHASE3
- Conditions
- Esophageal Neoplasms
- Interventions
- Pembrolizumab, Placebo, Cisplatin, 5-FU
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2021-07-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03189719?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03189719-1bf13b30